MAPLE GROVE, Minn. — Upsher-Smith Laboratories LLC has launched an enhanced website for its Qudexy XR anti-epileptic and migraine medication.

Upsher-Smith said Monday that QudexyXR.com features the company’s Access Pathways Program aimed at reducing the barriers associated with prescribing Qudexy XR (topiramate).

QudexyXR.com also offers health care providers tools necessary to help their patients “Start, Stay and Save” on Qudexy XR therapy, including an informational video, a guide on how to begin and a patient enrollment form, according to the company.

Besides being indicated to treat certain types of seizures, Qudexy XR extended-release capsules earlier this year received Food and Drug Administration approval for use in the prevention of migraine headache in adults and adolescents ages 12 and older.

“Upsher-Smith understands that access and affordability for extended-release brand products can be a challenge for patients and an administrative hurdle for physician offices,” stated Rusty Field, president and chief executive officer of Upsher-Smith. “The updated website offers resources that will provide eligible patients co-pay assistance and administrative support to practitioners that will allow them to prescribe Qudexy XR with greater ease.”

Eligible patients enrolled in the Access Pathways Program receive a $0 co-payment offer. Cash-paying patients, or those who may not have insurance, will benefit from a low-cost option, Upsher-Smith said. The program also offers benefit verification, prior authorization support, an e-voucher pharmacy finder and pharmacy stocking assistance.